SCHEMBL13627355

SCHEMBL13627355

CCONC(=O)CC(=O)Nc1cccc(CN(C(=O)OC(C)(C)C)[C@@H](Cc2ccccc2)C(=O)OCC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
TP53 P04637 1/20 0.42
BACE1 P56817 5/20 0.40
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 2/20 0.36
NTSR1 P30989 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPY1R P25929 1/20 0.36
NPY2R P49146 1/20 0.36
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
SLC1A2 P43004 1/20 0.35
SLC1A1 P43005 1/20 0.35
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627358 0.93 BACE1 (0.39) ALDH1A1TP53BACE1SMN1; SMN2SLC1A2
SCHEMBL1491418 0.81 ALDH1A1 (0.43) ALDH1A1TP53BACE1LMNAPOLB
SCHEMBL1491415 0.81 ALDH1A1 (0.43) ALDH1A1TP53BACE1LMNAPOLB
SCHEMBL1491432 0.77 CYP2D6 (0.47) ALDH1A1MAPTTDP1LMNAPOLB
SCHEMBL1491427 0.77 CYP2D6 (0.47) ALDH1A1MAPTTDP1LMNAPOLB
SCHEMBL10955821 0.76 ALDH1A1 (0.45) ALDH1A1TP53LMNAPOLBHSD17B10
SCHEMBL10955818 0.76 ALDH1A1 (0.45) ALDH1A1TP53LMNAPOLBHSD17B10
SCHEMBL6600202 0.70 MMP8 (0.46) ALDH1A1LMNAPOLBHSD17B10L3MBTL1
SCHEMBL7408424 0.70 ALDH1A1 (0.41) ALDH1A1TP53BACE1MAPTNPSR1
SCHEMBL18359864 0.70 ALDH1A1 (0.48) ALDH1A1LMNAPOLBHSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291978-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291978-A1 Enzyme Inhibitors HAT1, NR2E1, NR2C2 ALDH1A1 1343/4885TP53 2646/4885BACE1 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.